01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier Brandicourt...
16:33 , Jan 26, 2018 |  BC Week In Review  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Jan. 19,...
19:50 , Jan 22, 2018 |  BC Extra  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Friday before...
19:07 , May 26, 2017 |  BioCentury  |  Finance

Fast cash

HBM Healthcare Investments will see a quick return on its investment in True North Therapeutics Inc. less than a year after joining the Orphan hematology company’s investor syndicate. Bioverativ Inc. (NASDAQ:BIVV) agreed to buy True...
12:24 , May 26, 2017 |  BC Week In Review  |  Company News

Bioverativ aquiring True North

Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009, which has completed a Phase Ib trial to...
21:23 , May 23, 2017 |  BC Extra  |  Company News

Bioverativ acquiring True North

Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009, which has completed a Phase Ib study to...
07:00 , Oct 31, 2016 |  BioCentury  |  Finance

Complement cash

True North Therapeutics Inc.’s first clinical data for lead molecule TNT009 convinced new investor HBM Healthcare Investments to co-lead this month’s $45 million series D round. The other co-leads were new investor Redmile Group and existing...
07:00 , Oct 18, 2016 |  BC Extra  |  Financial News

True North raises $45M series D

Rare disease play True North Therapeutics Inc. (South San Francisco, Calif.) raised $45 million in a series D round led by new investors HBM Healthcare Investments and Redmile Group and existing investor Perceptive Advisors. New...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

TNT009: Interim Phase Ib data

Interim data from 5 patients with cold agglutinin disease (CAD) in Part C of a 3-part, double-blind, Austrian Phase Ib trial showed that a single dose of 10 mg/kg IV TNT009 followed by 60 mg/kg...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

True North Therapeutics hematology news

True North launched COMPASS, a patient registry for patients with cold agglutinin disease (CAD), a rare type of autoimmune hemolytic anemia. The company said the registry is “designed to build a deeper understanding of the...